JAG1 — Jagged Canonical Notch Ligand 1

The JAG1 gene provides instructions for making a protein called Jagged-1, which acts like a key that fits into a lock (the Notch receptor) on neighboring cells. This interaction sends important signals that tell cells how to develop and what type of cell to become during the growth of a baby in the womb. It is especially important for the normal development of the liver, heart, skeleton, and eyes. When there is a mutation or change in the JAG1 gene, the body doesn't produce enough working Jagged-1 protein. This disrupts the signaling process, leading to improper development of various organs. For example, it can cause a shortage of bile ducts in the liver, leading to liver damage, or it can cause structural problems in the heart, such as Tetralogy of Fallot. These health issues are commonly seen in a condition called Alagille syndrome.

Gene description: The JAG1 gene encodes the Jagged-1 protein, which is a canonical ligand for multiple Notch receptors. It plays a crucial role in the Notch signaling pathway, mediating cell fate decisions during embryonic development and is primarily associated with Alagille syndrome when mutated.

Patient and family guide: The JAG1 gene provides instructions for making a protein called Jagged-1, which acts like a key that fits into a lock (the Notch receptor) on neighboring cells. This interaction sends important signals that tell cells how to develop and what type of cell to become during the growth of a baby in the womb. It is especially important for the normal development of the liver, heart, skeleton, and eyes. When there is a mutation or change in the JAG1 gene, the body doesn't produce enough working Jagged-1 protein. This disrupts the signaling process, leading to improper development of various organs. For example, it can cause a shortage of bile ducts in the liver, leading to liver damage, or it can cause structural problems in the heart, such as Tetralogy of Fallot. These health issues are commonly seen in a condition called Alagille syndrome.

Gene function: The JAG1 gene encodes a type I transmembrane protein that acts as a ligand for Notch receptors. Binding of JAG1 to Notch receptors triggers a cascade of proteolytic cleavages, releasing the Notch intracellular domain to activate transcription factors essential for cell differentiation and morphogenesis.

Protein structure: JAG1 is a type I transmembrane protein with a small intracellular domain and a large extracellular region. The extracellular part includes a signal peptide, a DSL domain for Notch binding, 16 EGF-like repeats, and a cysteine-rich domain.

Molecular function: JAG1 functions as a cell surface ligand that binds to Notch receptors on adjacent cells. This interaction induces proteolytic cleavage of the Notch receptor, releasing its intracellular domain (NICD), which translocates to the nucleus to regulate the transcription of target genes like Hes1 and Hey1. This canonical Notch signaling pathway is vital for determining cell fate, proliferation, and differentiation across various tissues during development.

Mutation spectrum: The mutation spectrum of JAG1 includes full gene deletions, nonsense mutations, missense mutations, small deletions, small insertions, and splice site mutations. The majority of these are protein-truncating mutations that lead to haploinsufficiency, while a smaller percentage are non-truncating missense mutations.

Clinical significance: Mutations in the JAG1 gene, including deletions, nonsense, missense, and frameshift mutations, lead to haploinsufficiency or altered protein function. This disrupts the Notch signaling pathway, which is critical for cell fate determination and development. The disruption causes developmental defects in multiple organ systems, resulting in conditions like Alagille syndrome, characterized by bile duct paucity, cardiac defects, skeletal abnormalities, and facial dysmorphism.

Inheritance: Autosomal Dominant

Chromosomal location: 20p12.2

Research and therapeutic approaches: Current treatments for JAG1-related conditions like Alagille syndrome focus on symptom management, such as Ileal Bile Acid Transporter (IBAT) inhibitors for pruritus or surgical interventions like liver transplantation. Emerging therapeutic approaches aim to target the underlying cause, including gene editing to correct mutations, or biomedical engineering strategies for the delivery of exogenous JAG1 to restore Notch signaling.